Quality of life · Patients with active mild to moderate ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Total adverse events · Patients with active mild to moderate ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · Patients with active mild to moderate ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Primary outcome: Global improvement of disease activity or damage assessed by a medical practitioner or by participants · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
1 finding from 1 review
Adverse events associated with treatment · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
Medium‐dose UVA‐1 phototherapy (50 J/cm²) showed no clear difference in primary outcome: Adverse effects compared with low‐dose UVA‐1 phototherapy (20 J/cm²) (low certainty).
1 finding from 1 review
Secondary outcome: Improvement of disease activity (skin softening) · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
1 finding from 1 review
Secondary outcome: Improvement of disease damage ‐ not measured · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
The review found no eligible studies for this question.
1 finding from 1 review
All‐cause mortality · adults (18 years of age or older) with hypertension‐induced left ventricular hypertrophy
It is very uncertain whether antihypertensive therapy changes all‐cause mortality compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Cardiovascular events · adults (18 years of age or older) with hypertension‐induced left ventricular hypertrophy
It is very uncertain whether antihypertensive therapy changes cardiovascular events compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Total serious adverse events · adults (18 years of age or older) with hypertension‐induced left ventricular hypertrophy
It is very uncertain whether antihypertensive therapy changes total serious adverse events compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Heart failure hospitalisation (RR) · adults (18 years of age or older) with hypertension‐induced left ventricular hypertrophy
It is very uncertain whether antihypertensive therapy changes hospitalisation for heart failure compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults (18 years of age or older) with hypertension‐induced left ventricular hypertrophy
It is very uncertain whether antihypertensive therapy changes withdrawal due to adverse events compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Exacerbation requiring ED or hospital visit Weighted mean duration of studies: 31 weeks · people with asthma
It is very uncertain whether sublingual immunotherapy changes exacerbation requiring ED or hospital visit Weighted mean duration… compared with control (very low certainty).
1 finding from 1 review
Quality of life · people with asthma
The review found no eligible studies for this question.
1 finding from 1 review
Serious adverse events Weighted mean duration of studies: 49 weeks · people with asthma
Sublingual immunotherapy showed no clear difference in serious adverse events Weighted mean duration of studies: 56 weeks compared with control (moderate certainty).
1 finding from 1 review
Exacerbation requiring OCS Weighted mean duration of studies: 25 weeks · people with asthma
It is very uncertain whether sublingual immunotherapy changes exacerbation requiring OCS Weighted mean duration of studies: 58 weeks compared with control (very low certainty).
1 finding from 1 review
All adverse events Weighted mean duration of studies: 60 weeks** · people with asthma
Sublingual immunotherapy leads to higher all adverse events Weighted mean duration of studies: 62 weeks** compared with control (high certainty).
1 finding from 1 review
Bronchial provocation · people with asthma
1 finding from 1 review
ICS use · people with asthma
1 finding from 1 review
PTSD severity (post‐treatment) ‐ standardized difference · adults aged ≥ 16 years with PTSD
1 finding from 1 review